Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Gene therapy breakthrough for rare childhood disease?

NCT ID NCT06149403

First seen Jan 07, 2026 · Last updated May 25, 2026 · Updated 25 times

Summary

This study tests a new gene therapy, OTL-203, for children with Hurler syndrome, a rare genetic disease that damages organs and the brain. It compares the gene therapy to the current standard treatment, a stem cell transplant. The goal is to see if the gene therapy can prevent death, the need for another transplant, or severe health problems.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MPS-IH (HURLER SYNDROME) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Manchester University NHS Foundation Trust Blood and Marrow Transplant Programme, Royal Manchester Children's Hospital

    Manchester, M13 9WL, United Kingdom

  • Ospedale San Raffaele

    Milan, 20131, Italy

  • Princess Maxima Center

    Utrecht, 3584 CS, Netherlands

  • UMC Utrecht

    Utrecht, 3584 CX, Netherlands

  • University of Minnesota, Pediatrics

    Minneapolis, Minnesota, 55455, United States

Conditions

Explore the condition pages connected to this study.